odetiglucan

An injectable formulation of the polysaccharide beta-1,3/1,6 glucan derived from the cell wall of a strain from the yeast Saccharomyces cerevisiae and pathogen-associated molecular pattern (PAMP) molecule, with potential immunomodulating and antineoplastic activities. Upon administration, odetiglucan binds to innate immune effector cells through complement receptor 3 (CR3) and Fc gamma receptor IIA (FcgammaIIA; CD32A), thereby activating innate immune cells and enabling direct killing of tumor cells. In addition, odetiglucan repolarizes the immunosuppressive tumor microenvironment (TME), shifts the suppressive M2-state macrophages to a more M1 pro-inflammatory state, activates the maturation of antigen presenting cells (APCs), enables CD4 and CD8 T-cell expansion, and increases production of certain anti-tumor cytokines, such as interferon gamma (IFNg). Altogether, this induces and enhances anti-tumor immune responses.